Prolias Technologies, Inc. Acquires Commercial Stage microRNA Diagnostic Portfolio From Cornell University
6/19/2012 10:04:27 AM
NEW YORK--(BUSINESS WIRE)--Prolias Technologies, Inc., an emerging molecular diagnostics company focusing on predictive and prognostic genetic cytology and pathology, announced today that it has licensed from Cornell University a portfolio of intellectual property in the area of microRNA diagnostics developed at the Weill Cornell Medical College. The first series of intellectual property includes a panel that accurately differentiates malignant from benign indeterminate thyroid nodules. Prolias will commercially launch this microRNA panel, branded THYMIRA™, in the coming months. In addition to the THYMIRA™ panel, Prolias Technologies has also licensed a sophisticated proprietary computational algorithm to interpret results with a high level of confidence.